Skip to content
Thermo Fisher Scientific logo

TMO

Thermo Fisher Scientific

NYSEHealth CareDiagnostics & ResearchSnapshot 2026-05-08

$465.00-1.99%
Close 2026-05-08 · 1-day change
The bottom line

As of May 8, 2026, TMO has a composite score of 14.0 and a signal label of "mild favorable." The score is influenced by a medium confidence level of 76.1 and strengths in quality (78.3) and macro factors (31.5). The analysis is provisional and reflects various scenarios that could impact the score, including potential guidance changes and sector trends.

Composite +14as of 2026-05-08

Price

Daily closes from AlphaVantage. Earnings/event dots are placed inline.

Close 2026-05-08
Daily closes. Scroll over the chart to zoom; click a range to reset.
EarningsMaterial event

Factor signals

Read top-to-bottom: thesis (is this a strong company over a 1–3 year hold), watch flags (has something changed worth re-reading), and position context (how violent might the path be). Each pill is a parallel diagnostic — never aggregated into a single score.

L1

Thesis

is this a strong company over a 1–3 year hold?
F1 · Recent financial performance
strong
Top 30% of health care cohort
Why this rank
  • Direction share
    1.00
  • Slope (norm)
    0.04
  • Bonus
    0.00
Operating income, last 4 quarters ($M)
1663183419411899
F2 · Value
neutral
Mid-cohort by earnings yield
Why this rank
Price
$465.00
TTM EPS
$16.26
Earnings yield
3.5%
P/E (TTM)
28.6

Trailing four: 2024-Q3, 2025-Q1, 2025-Q2, 2025-Q3

F3 · Earnings quality
neutral
Mid-cohort cash conversion
Why this rank
TTM NI ($M)
3,875
TTM CFO ($M)
6,370
CFO/NI
1.64
L2

Watch

has something changed worth re-reading?
F4 · Management stability
neutral
Mid-cohort activity· see deep-dive ↓
capital friendlyTop 10% capital-friendly in health care cohort
Earnings setup · pre-print positioning
forward-looking
neutral14 analysts, 92% Buyfor period ending 2026-06-30
Why this setup
Consensus revisions

EPS estimate $5.81 → $5.72 (-1.5% / 30d). 2 raised, 12 cut, 14 covering analysts.

Rating actions

0 upgrades, 0 downgrades / 30d, 3 maintained. 92% of analysts rate Buy.

Price target activity

3 PT revisions / 30d. Avg target 32.2% above current price.

Material events

0 positive, 0 negative / 30d.

F4 · Management deep-dive — recent events, stated priorities, guidance track record
2

Stated priorities

2 priorityies extracted from earnings transcripts (as of 2026-05-08).

  1. 1.Complete acquisition of Clario Holdingsgrowthbehind14% progress
    3/24: Thermo Fisher announced the completion of its acquisition of Clario Holdings.
    Why this status

    Newly stated in 2026-Q1. The acquisition of Clario Holdings was completed as announced, indicating progress in expanding service offerings. No specific financial impact was detailed in the provided data, but the acquisition aligns with growth strategy.

  2. 2.Announce share buyback programcapital allocationmixed44% progress
    2/12: Thermo Fisher announced a share buyback program with the issuance of senior notes.
    Why this status

    Newly stated in 2026-Q1. Thermo Fisher announced a share buyback program, supported by the issuance of senior notes. The financials do not yet reflect the impact of this buyback, indicating it is in the early stages of execution.

3

Guidance track record

Insufficient guidance history for this ticker.

L3

Position context

how violent might the path be while I hold it?
Risk profile · realized
backward-looking
moderateworst 12m loss −28%, typical day ±1.2%
Why this risk level

Recent vol — 30d annualized 39%; 252d 31%.

Drawdown — Max 1y −28%. Bad day move −3%.

Beta to sector ETF (XLV) 1.21 over 1y.

Liquidity — score 100/100.

Sub-scores — vol 48/100, drawdown 45/100, beta 79/100, earnings vol .

Sector regime
headwind-15.1%sector vs S&P 500, 60d

via XLV

Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive — historically, headwind regimes have averaged stronger forward returns than tailwind.

AI cycle regime · market-wide
2-axis classifier
HeatingManiaSquallCrisisEarnings →Mood ↑
HeatingE +0.13 · M +0.71
Single-axisCHASEz +2.97+1.285d

Context label only — describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.

Not investment advice. As of 2026-05-08.

3

What changed

The most important moves since the prior daily snapshot.

  1. No material changes since the prior snapshot.

No material changes since the prior snapshot.

as of 2026-05-08

4

Management scorecard

How management runs the business — capital, margins, balance sheet, and how reliably they guide and deliver.

Composite62.1 / 100
Capital allocation46
Earnings discipline96
Margin discipline70
Balance sheet55
Guidance credibility
Post-call reaction41
as of 2026-05-08
4

What management is focused on

Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.

  • #1

    Complete acquisition of Clario Holdings

    Growth

    Thermo Fisher aims to complete the acquisition of Clario Holdings to enhance its service offerings.

    Behind

    Newly stated in 2026-Q1. The acquisition of Clario Holdings was completed as announced, indicating progress in expanding service offerings. No specific financial impact was detailed in the provided data, but the acquisition aligns with growth strategy.

    14%
    CEO/CFO:Thermo Fisher announced the completion of its acquisition of Clario Holdings.
    Press releaseSource dated 2026-03-24Stated 1 of last 8 quartersFirst seen 2026-03-24
    Show history (1)
    • 2026-Q1Press release

      Thermo Fisher announced the completion of its acquisition of Clario Holdings.

  • #2

    Announce share buyback program

    Capital allocation

    Thermo Fisher announced a share buyback program to return value to shareholders.

    Mixed

    Newly stated in 2026-Q1. Thermo Fisher announced a share buyback program, supported by the issuance of senior notes. The financials do not yet reflect the impact of this buyback, indicating it is in the early stages of execution.

    44%
    CEO/CFO:Thermo Fisher announced a share buyback program with the issuance of senior notes.
    Press releaseSource dated 2026-02-12Stated 1 of last 8 quartersFirst seen 2026-02-12
    Show history (1)
    • 2026-Q1Press release

      Thermo Fisher announced a share buyback program with the issuance of senior notes.

as of 2026-05-08
5

How this stock is priced

Two ways to read price: against peers in the same business, and against the company's own history.

Compared to peers
36higher = cheaper

Looks more expensive than peers.

Compared to its own history
higher = cheaper

Self-history needs ~20 months of data.

P/E
20.5x
EV/EBITDA
FCF yield
3.8%

P/E over the last 5 years

0 monthly points
Self-history needs ~20 months of TTM data; this ticker isn’t there yet.
fullas of 2026-05-08
7

How this compares

A side-by-side read on composite, valuation, and risk versus peers.

StockCompositeValuationRisk
TMO
Thermo Fisher Scientific
+14fullmoderate
LLY
Lilly (Eli)
+21fullmoderate
JNJ
Johnson & Johnson
+18fulllow
ABBV
AbbVie
+12fairlow
UNH
UnitedHealth Group
+24fairelevated
8

Risk — how this stock moves

What a normal day looks like, what a bad day looks like, and the worst the last year has thrown at it.

A typical day
How much price usually moves either way.
1.2%
A bad day (95th %ile)
A rough but not unusual down day.
-2.6%
Worst 12-month loss
Deepest peak-to-trough drop in the last year.
-27.6%
Earnings-day move
How much price usually moves on earnings day.
moderateas of 2026-05-08
9

What could change this view

Conditional scenarios — if X happens, the score would shift by about Y points. These are not predictions.

Upside triggers
  • If health_care sector trend rises from +0.06 into 'improving' (>= +0.20)+5.0 pts
  • If next-quarter guidance is raised (currently NEW as of 2026-04-23)+4.0 pts
Downside triggers
  • If next-quarter guidance is cut (currently NEW as of 2026-04-23)-8.0 pts
  • If labor state reverses from -0.31 (negative) to +0.31 (positive)-6.8 pts
  • If health_care sector trend falls from +0.06 into 'weakening' (<= -0.20)-5.0 pts
10

Material updates

Recent SEC 8-K filings ranked by likely impact, confidence, and recency.

  1. 2026-04-2315d agoItem 2.02

    Results of Operations and Financial Condition. On April 23, 2026, the Registrant announced its financial results for the fiscal quarter ended March 28, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Form 8-K and incorporated herein by reference. The information contained in this report and exhibits hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") o…

    earnings preannouncementneutralscore 46
  2. 2026-03-241mo agoItem 8.01

    Other Events. On March 24, 2026, Thermo Fisher Scientific Inc. (“Thermo Fisher”) issued a press release announcing the completion of its acquisition of Clario Holdings, Inc. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

    mna activitypositivescore 18
  3. 2026-02-122mo agoItem 1.01

    Entry into a Material Definitive Agreement. On February 12, 2026, Thermo Fisher Scientific Inc. (the “Company”) issued $1,000,000,000 aggregate principal amount of 4.215% Senior Notes due 2031 (the “2031 Notes”), $750,000,000 aggregate principal amount of 4.550% Senior Notes due 2033 (the “2033 Notes”), $1,300,000,000 aggregate principal amount of 4.902% Senior Notes due 2036 (the “2036 Notes”) and $750,000,000 aggregate principal amount of 5.546% Senior Notes due 2046 (the “2046 Notes” and,…

    capital allocationpositivescore 9
  4. 2026-02-122mo agoItem 8.01

    Other Events. The sale of the Notes was made pursuant to the terms of an Underwriting Agreement, which the Company entered into on February 9, 2026 (the “Underwriting Agreement”), with Deutsche Bank Securities Inc., RBC Capital Markets, LLC, SMBC Nikko Securities America, Inc. and Wells Fargo Securities, LLC, as representatives of the several underwriters named in Schedule A to the Underwriting Agreement. The Company expects that the net proceeds from the sale of the Notes will be approximate…

    capital allocationpositivescore 7
  5. 2026-01-293mo agoItem 2.02

    Results of Operations and Financial Condition. On January 29, 2026, the Registrant announced its financial results for the fiscal quarter and year ended December 31, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Form 8-K and incorporated herein by reference. The information contained in this report and exhibits hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Ex…

    earnings preannouncementneutralscore 7
11

Score history

The composite score, snapshot by snapshot. The dotted line at zero separates leaning-positive from leaning-negative.

60 snapshots
Data freshness · As of 2026-05-08 · Macro 2026-05-08 · Sector 2026-05-07 · Fundamentals 2026-02-26 · Price 2026-05-07 · Generated 2026-05-08 · Spec 2.3

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.